| 5.05 0.49 (10.75%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.64 | 1-year : | 7.52 |
| Resists | First : | 5.68 | Second : | 6.44 |
| Pivot price | 5.54 |
|||
| Supports | First : | 4.46 | Second : | 3.71 |
| MAs | MA(5) : | 5.29 |
MA(20) : | 5.44 |
| MA(100) : | 6.45 |
MA(250) : | 7.64 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.6 |
D(3) : | 29.8 |
| RSI | RSI(14): 42  |
|||
| 52-week | High : | 17.39 | Low : | 4.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ KTTA ] has closed above bottom band by 20.2%. Bollinger Bands are 17% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.17 - 5.21 | 5.21 - 5.24 |
| Low: | 4.94 - 4.98 | 4.98 - 5.02 |
| Close: | 4.98 - 5.05 | 5.05 - 5.11 |
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Mon, 29 Apr 2024
Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting - Yahoo Finance
Mon, 15 Apr 2024
11 Undervalued Stocks for Less Than $50 in April 2024 - Investopedia
Wed, 12 Oct 2022
Pasithea Therapeutics Acquires AlloMek Therapeutics - GlobeNewswire
Thu, 18 Aug 2022
Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - StockTitan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 140.8 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -13.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.6 % |
| Return on Equity (ttm) | -54.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -15.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.37 |
| PEG Ratio | 0 |
| Price to Book value | 0.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|